How has been the historical performance of the Bharat Immunolog?

Bharat Immunolog has experienced a declining trend in net sales and profitability, with net sales dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, and losses increasing from Rs 6.75 crore to Rs 17.06 crore in the same period. Despite a positive cash flow from operating activities in March 2023, the overall financial position remains weak.

Answer:<BR>The historical performance of Bharat Immunolog shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Bharat Immunolog's net sales have decreased from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023, reflecting a downward trend over the years. The total operating income followed a similar pattern, dropping from Rs 124.19 crore in March 2017 to Rs 44.61 crore in March 2023. The company has faced increasing raw material costs, which peaked at Rs 84.28 crore in March 2019 and fell to Rs 33.04 crore in March 2023. Operating profit margins have deteriorated significantly, with an operating profit margin of -41.38% in March 2023 compared to a positive margin of 9.9% in March 2017. The profit before tax has also worsened, moving from a profit of Rs 9.45 crore in March 2017 to a loss of Rs 22.85 crore in March 2023. Consequently, the profit after tax has shown a similar decline, with losses increasing from Rs 6.75 crore in March 2017 to Rs 17.06 crore in March 2023. The company's total liabilities decreased from Rs 191.70 crore in March 2022 to Rs 158.84 crore in March 2023, while total assets also fell from Rs 191.70 crore to Rs 158.84 crore in the same period. Cash flow from operating activities turned positive in March 2023 at Rs 10.00 crore, contrasting with a negative cash flow of Rs -42.00 crore in March 2022, although the overall cash position remains weak with a closing cash balance of Rs 1.00 crore in March 2023.

When is the next results date for Bharat Immunolog?

No Upcoming Board Meetings

Has Bharat Immunolog declared dividend?

No Dividend History Available

Who are the peers of the Bharat Immunolog?

Bharat Immunolog's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Mercury Labs, Makers Labs, Ind-Swift, and Ajooni Biotech. Bharat Immunolog has below-average management risk and growth, with a 1-year return of -8.98%, higher than Ind-Swift but lower than its other peers.

Peers: The peers of Bharat Immunolog are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Mercury Labs, Makers Labs., Ind-Swift, Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Mercury Labs and Onyx Biotec. Below Average management risk is noted for Bharat Immunolog, Makers Labs., and Ajooni Biotech, while Ind-Swift does not qualify. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Bharat Immunolog, Divi's Lab., Torrent Pharma, Mercury Labs, Makers Labs., Ajooni Biotech, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good is noted for Torrent Pharma, Average for Ajooni Biotech, and Below Average for Bharat Immunolog, Makers Labs., and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ind-Swift has the lowest at -19.94%. Bharat Immunolog's 1-year return is -8.98%, which is higher than Ind-Swift but lower than all other peers. Additionally, Mercury Labs, Makers Labs., Ind-Swift, and Ajooni Biotech have negative six-month returns.

Should I buy, sell or hold Bharat Immunolog?

Is Bharat Immunolog overvalued or undervalued?

As of April 5, 2023, Bharat Immunolog is considered overvalued and classified as "risky" due to negative financial metrics, including a PE Ratio of -6.21 and an EV to EBITDA of -10.01, which compare unfavorably to peers like Sun Pharma and Cipla, alongside a 1-year stock return of -8.84% versus the Sensex's 7.62%.

As of 5 April 2023, Bharat Immunolog has moved from a grade of "does not qualify" to "risky." The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of -6.21, an EV to EBITDA of -10.01, and a Price to Book Value of 1.43. These figures indicate significant financial distress, particularly highlighted by the negative PE and EV ratios.<BR><BR>In comparison to its peers, Bharat Immunolog's valuation appears unfavorable. For instance, Sun Pharma has a PE Ratio of 35.25, while Cipla stands at 22.99, both indicating a more favorable market perception. The company's recent stock performance has also lagged behind the Sensex, with a 1-year return of -8.84% compared to the Sensex's 7.62%. Overall, the combination of poor financial ratios and unfavorable peer comparisons suggests that Bharat Immunolog is overvalued in the current market environment.

What is the technical trend for Bharat Immunolog?

As of May 13, 2025, Bharat Immunolog's trend is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands across different time frames.

As of 13 May 2025, the technical trend for Bharat Immunolog has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the Bollinger Bands show a bullish signal on the weekly chart but mildly bearish on the monthly. The KST is mildly bullish weekly but bearish monthly, and there are no clear trends indicated by Dow Theory on both weekly and monthly time frames. Overall, the current stance is mildly bearish, driven primarily by the mixed signals from moving averages and the monthly MACD.

Who are in the management team of Bharat Immunolog?

As of March 2022, the management team of Bharat Immunolog includes Y K Gupta (Chairman), Sanjay Kumar Mishra (Managing Director), and several independent directors: Alka Sharma, Mohd Aslam, Sudhanshu Vrati, Madhu Dikshit, and Pankaj Kumar, along with Sandip K Lal (Company Secretary).

As of March 2022, the management team of Bharat Immunolog includes the following members:<BR><BR>1. Y K Gupta - Chairman & Independent Director<BR>2. Sandip K Lal - Company Secretary & Compliance Officer<BR>3. Alka Sharma - Independent Director<BR>4. Mohd Aslam - Independent Director<BR>5. Sudhanshu Vrati - Independent Director<BR>6. Madhu Dikshit - Independent Director<BR>7. Sanjay Kumar Mishra - Managing Director<BR>8. Pankaj Kumar - Independent Director<BR><BR>This team comprises a mix of independent directors and key management personnel, each contributing to the governance and operational oversight of the company.

What does Bharat Immunolog do?

Bharat Immunological & Biological Corporation Ltd (BIBCOL) manufactures vaccines and pharmaceutical products and operates as a Central Public Sector Unit. As of September 2023, it reported a net profit of -49 Cr and has a market cap of INR 100 Cr.

Overview: <BR>Bharat Immunological & Biological Corporation Ltd (BIBCOL) is engaged in the manufacture of vaccines and pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>BIBCOL was incorporated in 1989 and operates as a Central Public Sector Unit under the Department of Biotechnology, Ministry of Science and Technology. The latest quarterly results reported are for September 2023.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -49 Cr (Quarterly Results - Sep 2023) <BR>Market-cap value: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.83 <BR>Return on Equity: -22.96% <BR>Price to Book: 1.27<BR><BR>Contact Details: <BR>Address: BIBCOL OPV Plant Village Chola, Bulandshahr, Uttar Pradesh: 203203 <BR>Tel: 91-5732-238210 <BR>Website: http://www.bibcol.com

Who are the top shareholders of the Bharat Immunolog?

The top shareholders of Bharat Immunolog include the President of India, who holds 59.25% of the shares, while individual investors own 39.47%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Bharat Immunolog are primarily the promoters, with the President of India holding the largest share at 59.25%. Additionally, individual investors collectively hold 39.47% of the shares. There are currently no mutual funds or foreign institutional investors involved in the company's shareholding.

How big is Bharat Immunolog?

As of 24th July, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 98.00 Cr, with Net Sales of 7.65 Cr and a Net Profit loss of 18.07 Cr over the latest four quarters. Shareholder's Funds are 87.80 Cr, and Total Assets are valued at 158.84 Cr as of March 2023.

As of 24th July, Bharat Immunological & Biological Corporation Ltd has a market capitalization of 98.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bharat Immunological reported Net Sales of 7.65 Cr. However, the company experienced a loss of 18.07 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2023. Shareholder's Funds stand at 87.80 Cr, while Total Assets are valued at 158.84 Cr.

Which are the latest news on Bharat Immunolog?

Why is Bharat Immunolog falling/rising?

As of 03-Dec, Bharat Immunological & Biological Corporation Ltd's stock is experiencing a short-term rise of 1.66% after three days of decline, indicating a potential trend reversal. However, it remains below its moving averages, suggesting a longer-term downward trend despite increased investor participation.

As of 03-Dec, Bharat Immunological & Biological Corporation Ltd's stock price is rising, as indicated by a change of 0.33 (1.66%) upwards. This increase comes after three consecutive days of decline, suggesting a trend reversal. Additionally, the stock has outperformed its sector by 1.67% today, which may reflect a positive shift in investor sentiment. <BR><BR>Despite the current rise, it is important to note that the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a longer-term downward trend. However, there has been a significant increase in investor participation, with delivery volume rising by 175.55% compared to the 5-day average, which may contribute to the current upward movement in price. <BR><BR>Overall, while the stock is experiencing a short-term rise, it is still facing challenges in the broader context of its performance over the past weeks and months.